Tag: MER511
-
Eli Lilly to Acquire Merida Biosciences for Up to $2.875 Billion
Eli Lilly will acquire Merida Biosciences for up to $2.875 billion, gaining a precision autoantibody-degradation platform and multiple immunology programs.
-
How MER511 Selectively Removes Pathogenic Autoantibodies in Graves’ Disease
Scientific thumbnail showing how MER511 removes pathogenic TSHR autoantibodies and reduces abnormal TSHR–cAMP signaling in Graves’ disease.